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Abstract
Background: RNA inhibition by siRNAs is a frequently used approach to identify genes required for specific
biological processes. However RNAi screening using siRNAs is hampered by non-specific or off target effects of the
siRNAs, making it difficult to separate genuine hits from false positives. It is thought that many of the off-target
effects seen in RNAi experiments are due to siRNAs acting as microRNAs (miRNAs), causing a reduction in gene
expression of unintended targets via matches to the 6 or 7 nt ‘seed’ sequence. We have conducted a careful
examination of off-target effects during an siRNA screen for novel regulators of the TRAIL apoptosis induction
pathway(s).
Results: We identified 3 hexamers and 3 heptamer seed sequences that appeared multiple times in the top
twenty siRNAs in the TRAIL apoptosis screen. Using a novel statistical enrichment approach, we systematically
identified a further 17 hexamer and 13 heptamer seed sequences enriched in high scoring siRNAs. The presence of
one of these seeds sequences (which could explain 6 of 8 confirmed off-target effects) is sufficient to elicit a
phenotype. Three of these seed sequences appear in the human miRNAs miR-26a, miR-145 and miR-384.
Transfection of mimics of these miRNAs protects several cell types from TRAIL-induced cell death.
Conclusions: We have demonstrated a role for miR-26a, miR-145 and miR-26a in TRAIL-induced apoptosis. Further
these results show that RNAi screening enriches for siRNAs with relevant off-target effects. Some of these effects
can be identified by the over-representation of certain seed sequences in high-scoring siRNAs and we demonstrate
the usefulness of such systematic analysis of enriched seed sequences.
Background
TNF-related apoptosis inducing ligand (TRAIL) induces
apoptosis in many transformed cell types but not in
most normal cell types [1,2]. This makes it an attractive
option for anti-cancer treatment. Indeed several clinical
trials are underway using either recombinant ligand or
antibodies targeted at the TRAIL receptors [3]. How-
ever, not all tumour cells are sensitive to TRAIL and the
mechanism underlying resistance to TRAIL killing is not
fully understood.
TRAIL stimulates apoptosis by binding to one of two
receptors, TNFRSF10A and TNFRSF10B [4,5]. This
leads to the recruitment of FADD and Caspase-8,
which leads, in turn, both to the direct activation of
the executioner caspase, Caspase-3, and to the activa-
tion of the mitochondrial apoptosis pathway via the
cleavage of BID [6,7]. Mitochondrial pathway activa-
tion results both in the activation of Caspase-3 by
Caspase-9 and also relief of Caspase-3 inhibition by
the protein DIABLO [8].
Investigations into the mechanisms that regulate sensi-
tivity of cells to TRAIL have implicated many factors
and pathways. Regulation of the TRAIL receptors, at the
level of expression, localisation to the cell surface and
the O-glycosylation of the proteins, partially, but not
fully correlates with sensitivity [9-11]. Levels of the
CFLAR (also known as cFLIP) apoptosis inhibitory fac-
tor has also been associated with TRAIL resistance,
although there is not a correlation in all cases [9,10].
Other factors that have been implicated include MYC,
RAS, Protein Kinase C, ATK and IGF1 [12-20].
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interference (RNAi) are an increasingly popular method
for finding genes associated with cellular phenotypes.
Indeed two screens for genes involved in TRAIL-
induced apoptosis have been undertaken [17,21]. Despite
screening many of the same genes, only a single gene
was identified in both screens. This could be an indica-
tion that these screens were not saturating, that there
are cell-type specific differences, or that the confirma-
tion procedures/control of off-target effects were insuffi-
cient in one or both screens.
Off-target effects in RNAi screens occur where short
interfering RNAs (siRNAs) directly affect the expression
of genes other than the one that they are designed to
target. Micro-array experiments have shown that an
siRNA can affect the mRNA levels of many genes
[22,23]. There is growing evidence that at least some of
these effects are due to siRNAs acting as microRNAs
(miRNAs), targeting transcripts which contain matches
in their 3’ untranslated regions (UTRs) to 6 or 7 nucleo-
tide sequences at the 5’ end of the siRNAs (nucleotides
2 to 7 or 8, the seed sequence). Firstly the transcripts
shown to be reduced after siRNA transfection in micro-
array experiments correlate with the presence and num-
ber of matches to the seed sequence of the transfected
siRNAs, but not with overall identity between the
siRNA and the best match in an mRNA [22]. Secondly,
the degradation products of mRNAs with an imperfect
match to an siRNA do not correlate with the canonical
cleavage site associated with RNAi induced degradation,
but are more random, as in miRNA-induced de-stabili-
sation of mRNA [24]. Finally, siRNAs can affect the pro-
tein levels of mis-matched targets, without affecting the
mRNA levels, particularly if GU base pairing is present
[24,25].
Such off-target effects have been shown to cause pro-
blems in siRNA based screens. In a screen for genes which
sensitize normally resistant cells to a Bcl-2 inhibitor, Lin
et al f o u n dt h a tt h e i rt o pt h r e eh i t ss c o r e dw e l ld u et o
off-target effects. They observed that two of these three
siRNAs shared the same 7 nt seed sequence. Searching a
database of 3’ UTRs, they found that the Bcl-2 family
member Mcl-1 contained matches to both the 7 nt seed
sequences seen in their top three siRNAs. They hypothe-
sised that screening enriches for siRNAs with off-target
effects and that this will lead to enrichment of certain seed
sequence in high scoring siRNAs [26].
Until now, such effects in siRNA screens have only
been described as post-hoc explanations for already
identified off-target effects, generally restricted to the
seeds of the top few siRNAs from a hit list. To the best
of our knowledge, systematic analyses of the effects of
seed sequences on siRNA screen results have yet to
be reported. Therefore, here we report a screen for
regulators of the TRAIL-induced apoptosis pathway.
After rigorous confirmation of a set of hits, we investi-
gated the off-target effects in our results. We show both
that a set of seed sequences is over-represented in our
potential hit siRNAs and that a second, overlapping set
of seed sequences is enriched in high scoring siRNAs in
general and that the presence of one of these seed
sequences is sufficient to render an siRNA active in our
screen. This effect was used to identify three species of
miRNA that are regulators of the TRAIL induced apop-
tosis pathway.
Results and Discussion
A screen for novel regulators of the TRAIL-induced
pathway
In order to confirm that our assay is capable of identify-
ing novel genes in the TRAIL-induced apoptosis path-
way we selected 18 genes previously implicated in the
pathway, including several genes identified in a previous
screen, in addition to genes central to the apoptosis
pathway [17]. We measured the effect of transfecting
siRNAs targeting these genes on the sensitivity of HeLa
cells to TRAIL-induced cell death. 50% of these siRNAs
significantly reduced the sensitivity of cells to TRAIL-
induced cell death, including 5/5 core death pathway
genes (BID, CASP3, CASP8, DIABLO and TNFRSF10A,
Figure 1). Comparing the TRAIL sensitivity of cells
transfected with a negative control siRNA to cells trans-
fected with an anti-CASP8 siRNA, shows that the assay
had a Z’ score of 0.46 (data not shown). Z’ is a scale-
free measurement of the separation of two distributions
where scores of greater than zero indicate non-overlap-
ping distributions, while a score of one would indicate
infinite separation (either zero standard deviation for
each distribution or an infinite separation of the means)
[27]. This demonstrates the effectiveness of our RNAi
assay for identifying genes in the TRAIL pathway.
We next screened a library of 12,190 siRNAs, target-
ing the 6,095 genes of the druggable genome, excluding
kinase and phosphatase genes (which were screened
separately), in duplicate, for novel genes in the TRAIL-
induced cell death pathway (Figure 2a and Figure 2b,
complete results see Additional file 1). We undertook a
careful confirmation process for genes targeted by the
top 20 scoring siRNAs. Confirmation was based on two
criteria. First, at least two siRNAs targeting the gene
must have a significant effect in a second assay for sen-
sitivity to TRAIL-induced apoptosis. This secondary
assay took the form of a measurement of Caspase-3/7
activity levels following treatment with TRAIL. Cas-
pases-3 and -7 are executioner Caspases and so their
levels report directly on apoptosis, instead of cell death
in general (as in the primary assay). Second, at least two
of those siRNAs that have an effect in the secondary
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and this effect must be larger than any siRNA that does
not have a significant effect in the secondary assay (Fig-
ure 2c and Additional File 2, Figure S1). Thus, IGF1R is
counted as a hit because two siRNAs targeting it have a
significant effect on Caspase-3/7 levels, and both reduce
IGF1R transcript levels, while a third siRNA has no
effect on transcript levels and is thus excluded. Conver-
sely the effect LRPAP1 siRNAs was designated as ‘off-
target’ because although two of the three siRNAs target-
ing it had an effect on Caspase-3/7 induction, the
siRNA which did not have a significant phenotypic
effect produced a stronger knock-down at the mRNA
level than either of the siRNAs that did have an effect.
GPR132 is designated as ‘Unconfirmed’ because while
the siRNA that scored highly in the screen showed a
reproducible effect on Caspase-3/7 activation levels,
other siRNAs targeting GPR132 did not. However, none
of these other siRNAs reduced the levels of GPR132 as
efficiently as the first siRNA.
In five cases (IGF1R, MAX, MYC, PDE11A and TEGT),
we were able to confirm that the effect of siRNAs target-
ing these genes was due to on-target effects by these
criteria, therefore implicating these genes as genuine reg-
ulators of TRAIL-induced apoptosis. In the case of
PDE11A we were unable to detect expression in any
sample (possibly due to very low wild-type expression
levels), but included the gene in our hit list since we
found three siRNAs targeting PDE11A that have a signifi-
cant effect on Caspase-3/7 levels. Kinase and phosphatase
genes were investigated in a separate screen, but we were
unable to confirm any hits (data not shown).
MYC and IGF1R are both genes that have previously
been implicated in sensitivity to TRAIL [13,14,20]. MAX
is MYC’s dimerization partner and is required for both
the transcriptional activating and suppressing functions
of MYC [28]. That these genes are amongst our hit list
confirms the power of our screen for identifying genes
in the TRAIL pathway. PDE11A encodes a dual specifi-
city phosphodiesterase that hydrolyzes both cAMP and
cGMP and is up-regulated in some carcinoma cell types
[29,30]. Since cAMP is involved in the regulation of the
anti-apoptotic BCL-2 via CREB and AKT, this could
possibly implicate the IGF1-AKT pathway in the regula-
tion of TRAIL induced apoptosis, in agreement with the
finding that IGF1R is also involved [31].
The function of product of TEGT is not known, how-
ever, it has been shown to protect against several trig-
gers of apoptosis (but not FAS), the opposite of the
phenotype shown here [32]. How this factor might be
involved in the regulation of TRAIL-induced apoptosis
is unknown.
Enrichment of seed sequences in high scoring siRNAs
During the confirmation of our screening results we
encountered a large number of off-target effects - siR-
NAs which caused a phenotypic effect that was indepen-
dent of their effect of the transcript level of the intended
target. It is also worth noting that in several cases we
identified genes where knock-down by two siRNAs
induced TRAIL resistance, while a third siRNA did not,
despite reducing the mRNA levels further, suggesting
that the effect of both of the first two siRNAs were due
to off-target effects (Additional file 2, Figure S1). This
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Figure 1 Knock-down of many genes previously associated with the TRAIL pathway reduces sensitivity to TRAIL-induced cell death.
HeLa Cells were transfected with siRNAs targeting a selection of genes previously associated with TRAIL induced apoptosis. After 48 hrs the
sensitivity of cells to treatment with 1 μg/ml TRAIL was measured (see Materials and Methods). Error bars represent 1 standard deviation (n = 3),
* indicates significantly different from negative control (t-test on log-transformed data, Bonferroni correct p < 0.05).
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Figure 2 A screen for new modulators of the TRAIL-induced apoptosis pathway. 12,190 siRNAs targeting 6,095 genes were screened in
duplicate for genes affecting sensitivity to TRAIL induced pathway (see materials and methods). a) Distribution of scores for sample siRNAs.
Survival after treatment was median normalised by plate, a z-like score calculated using median and median absolute deviation and the
minimum of two replicates was selected for each siRNA (see methods and [45]). This score represents a normalized measure of the effect of a
particular siRNA compared to the majority of siRNAs and is robust to outliers. b) Boxplot of scores for each of groups of controls used in the
screen. NoT = Not Transfected c) Induction of Caspase-3/7 activity after 6 hrs treatment with 0.5 μg/ml TRAIL after knock-down of confirmed hit
genes with multiple siRNAs compared to induction in cells transfected with negative control siRNA. Error bars represent 1 standard deviation
(n = 3) all results are significant from negative control (P < 0.05, Students’ t-test).
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Page 4 of 12suggests that two independent siRNAs may not be suffi-
cient for confirming hits in siRNA screens.
Lin and colleagues previously found that all three of
the top siRNAs in an RNAi screen induced off-target
effects, that two of these three siRNAs shared the same
sequence in nucleotides 2-8 (similar to the seed
sequences of miRNAs) and that the off-target effects
were due to matches to these sequences [26]. To exam-
ine if a similar effect could be behind the off-target
effects in our screen we examined the hexamer (nucleo-
tides 2-7) and heptamer (nucleotides 2-8) seed
sequences of the 20 highest scoring siRNAs from our
screen (Table 1). Surprisingly several seed sequences
appear more than once in this list. In total 3 hexamers
appeared two or more times and one of these appears 4
times. Of these, 2 (CAAGGT and ACTTGA) appeared
twice and three times respectively in siRNAs that caused
a reproducible effect on TRAIL-induced Caspase-3/7
levels in confirmation assays. Three heptamer seed
sequences appear twice in the top 20 siRNAs, one of
which is found twice in siRNAs confirmed to have a
reproducible effect on TRAIL-induced Caspase-3/7
levels. To test the significance of these observations we
used a sampling approach (see materials and methods).
Finding that two siRNAs in the top 20 share a heptamer
seed sequence is significant (P < 0.045). Although obser-
ving two siRNA sharing a hexamer seed sequence is not
significant at the 5% level, observing two or more such
seeds is significant (P = 0.013), while finding four
siRNAs sharing a seed sequence is highly significant
(P < 0.0002). If only siRNAs with reproducible effects
are considered, finding two heptamers (P = 0.034) or
three hexamers (P = 0.001) is still significant.
Restricting our examination of seed sequences to the
t o p2 0s i R N A si sa r b i t r a r y .T h eG e n eS e tE n r i c h m e n t
Analysis (GSEA) algorithm tests for the enrichment of a
set of items within a larger ranked list of such items
[33]. In order to gain a more general view of the enrich-
ment of seed sequences in the high scoring siRNAs of
our screen we extracted the seed sequences of every
siRNA in the screen, created sets of siRNAs that shared
seed sequences and appliedt h eG S E Aa l g o r i t h mt o
identify seed sequences generally enriched in high scor-
ing siRNAs. Using a family-wide error rate corrected
P value threshold of 0.05 a total of 17 hexamer and 13
heptamer seeds were identified that were significantly
enriched in high scoring siRNAs (Table 2). This finding
confirms Lin et al’s hypothesis that screening itself
enriches for siRNAs with particular seed sequences.
From here on we use ‘enriched seed’ to refer to both
those seeds identified by GSEA and those that appear
multiple times in the 16 confirmed siRNAs.
Since siRNAs with these seeds have a tendency to
score highly, it is possible that they are scoring highly
Table 1 Seeds and Confirmation status of the top 20 siRNAs
Transcript Symbol Score Hexamer Seed Heptamer Seed Status Enriched Seed
NM_003217 TEGT 3.51 CAAGGT TCAAGGT OTE +
NM_016368 ISYNA1 3.43 TGTCCA GTGTCCA OTE *
NM_001240 CCNT1 3.28 CAAGGT TCAAGGT OTE +
NM_002197 ACO1 3.11 ACTTGA CACTTGA Unconfirmed +
NM_003947 HAPIP 2.88 ACTTGA TACTTGA OTE +
NM_002337 LRPAP1 2.8 TCACAA ATCACAA OTE +
NM_005799 INADL 2.76 ACTTGA AACTTGA OTE +
NM_003554 OR1E2 2.72 TTGTAA TTTGTAA Unconfirmed -
NM_013345 GPR132 2.68 AGATCA GAGATCA Unconfirmed +
NM_004584 RAD9A 2.65 TAAGGA CTAAGGA OTE -
NM_003266 TLR4 2.64 AAAGTT CAAAGTT Unconfirmed -
NM_000674 ADORA1 2.63 TAATAA CTAATAA OTE +
NM_002382 MAX 2.57 AAGAAA TAAGAAA Hit -
NM_006986 MAGED1 2.56 ACTTGA AACTTGA False +ve +
NM_000875 IGF1R 2.55 CACTTA ACACTTA Hit -
NM_016953 PDE11A 2.54 GTAAGA GGTAAGA Hit -
NM_014379 KCNV1 2.54 TGTCCA GTGTCCA False +ve *
NM_080674 C20orf86 2.52 CGTTGT GCGTTGT False +ve -
NM_002467 MYC 2.51 TTACAC GTTACAC Hit +
XM_497793 LOC402037 2.51 GCATTA GGCATTA False +ve -
Table shows the top 20 siRNAs from the screen, their status: Hit, False pos (did not repeat), Unconfirmed (that is this siRNA reproducibly affected caspase-3/7
activation levels, but we could not confirm the involvement of the gene targeted), or OTE (off-target effect), the hexamer and heptamer seed sequences
(sequences that appear more than once are shown in bold), and whether the seed is one which either appears more than once, or is in the set of enriched seed
sequences (see Table 2). * The seed sequence TGTCCA appears once in the OTE siRNA ISYNA1 and once in the false positive siRNA targeting KCNV1.
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because the intended target is involved in TRAIL-
induced apoptosis. To test if the presence of an enriched
seed alone could alter the sensitivity of cells to TRAIL
induced apoptosis, we transfected cells with either an
siRNA targeting Luciferase (siGL2), or anti-luciferase
siRNAs where the seed sequence (nucleotides 2-7) was
replaced with either the sequence ACTTGA (siGL2
+seed) or a version of the same sequence with two
bases exchanged (ATCTGA - siGL2+mutseed).
A C T T G Aa p p e a r si nt h es e e dp o s i t i o no f3o ft h e1 6
confirmed siRNAs, and was the second most enriched
seed sequenced identified by GSEA. Cells transfected
with the siRNA containing the mutated seed have a very
similar sensitivity to TRAIL-induced cell death to that
of cells transfected with the unaltered anti-Luciferase
siRNA (Figure 3). However, cells transfected with the
siRNA containing ACTTGA had a sensitivity close to
that of cells transfected with an anti-Caspase-8 siRNA.
Thus the presence of the seed sequence ACTTGA alone
in an otherwise non-effective siRNA can have a strong
effect on sensitivity to TRAIL-induced cell death.
In total 9 of the 16 siRNAs with a confirmed effect on
Caspase-3/7 actiavation contain a seed from one of
these two sets of sequences, including six of the top 7
siRNAs. This includes two siRNAs targeting genes that
had been selected as confirmed hits (siRNAs targeting
TEGT and MYC). In each of these cases we had found a
second siRNA targeting the gene that also had a signifi-
cant effect on TRAIL-induced apoptosis. However, in
the case of TEGT that other siRNA (which was the sec-
ond siRNA used in the screen) also contained one of
the enriched seed sequences. Given the amount of evi-
dence for the involvement of MYC in the TRAIL path-
way from the literature, it is unlikely that siRNAs
targeted against MYC exert their effect solely though
off-target effects [13,34-38]. Testing further siRNAs tar-
geting TEGT we were unable to confirm the involve-
ment of TEGT in TRAIL-induced apoptosis (Additional
file 2, Figure S2), thus changing the status of TEGT siR-
NAs from “hit” to “off-target”.
Of the 20 highest scoring siRNAs, 16 had a statistically
significant effect on TRAIL-induced cell death. The effects
of eight siRNAs could be shown to be due to off-target
effects, of which 6 (75%) have one of the enriched seed
sequences. In total the effects of the 12 of the 16 (75%)
siRNAs which reproducibly reduced the sensitivity of cells
to TRAIL-induced cell death could be attributed to either
t h et a r g e t i n go fah i tg e n eo rt h es e e ds e q u e n c eo ft h e
siRNA. We cannot say that all the genes targeted by an
siRNA containing a seed are definitely not involved in
TRAIL-induced apoptosis, just that at least part of their
effect is likely to be due to off-target effects. Even so the
majority of siRNAs in the top 20 appear to owe at least
part of their activity to off-target effects. Such findings
suggest that screening enriches for siRNAs with off-target
effects and that a high scoring siRNA in this assay is more
likely to exert its effect through an off-target effect than by
affecting the intended target. Thus off-target effects are
probably more widespread than is generally recognised.
The usual method for distinguishing true hits from
RNAi screens from off-targets is to require that two
independent siRNAs targeting the same gene have the
same phenotype [39]. However, one clear implication of
this study is that this is insufficient, particularly when
both siRNAs were used in the screen (as for TEGT in
this study). We recommend that hits should be con-
firmed using at least two, and ideally three or more siR-
NAs not used in the screen, and whose seeds have been
checked.
Table 2 Seed sequences enriched in high scoring siRNAs
Seed Size Normalized Enrichment Score FWER p-val
Hexamers
TAATAA 70 2.691 0
ACTTGA 14 2.674 0
CCTTAA 16 2.642 0
AATTAA 44 2.567 0
ACTGGA 10 2.510 0
TAGGAA 13 2.505 0
TAAAGA 20 2.482 0.002
GAATAA 21 2.474 0.002
AAGTTA 20 2.426 0.004
TCACAA 12 2.413 0.005
AAATGA 21 2.405 0.005
AGATCA 35 2.378 0.006
TTATAA 22 2.335 0.009
AATATT 15 2.314 0.015
AGATCT 17 2.304 0.015
TGAATA 16 2.255 0.026
CTGGAA 8 2.198 0.047
Heptamers
CAATTAA 18 2.911 0.000
GAGATCA 18 2.387 0.001
GAAAGAA 10 2.241 0.015
TTAATAA 17 2.227 0.015
GTATTTA 16 2.211 0.016
ATAGGAA 6 2.187 0.021
ACCTTAA 8 2.185 0.021
TAATTAA 8 2.179 0.024
TTAATTA 10 2.151 0.037
ACAATTA 10 2.148 0.039
AAGATCA 13 2.140 0.041
CTAATAA 20 2.139 0.041
CTAATTA 7 2.136 0.043
Table shows seed sequences designated enriched in high scoring siRNAs by
GSEA. The number the seeds in the set, the enrichment score and the
multiple testing corrected P value are shown.
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a substantial number of false positives in RNAi screens,
but can also mask true hits and thus increase false negative
rates. In the TRAIL-killing screen described here, we
tested for the enrichment of genes previously associated
with the TRAIL pathway. We identified 27 genes that had
previously been associated with the TRAIL induced apop-
tosis pathway and knockdown of which might be expected
to decrease sensitivity to TRAIL-induced cell death. siR-
NAs against 12 of these were present in our library
(BID, MYC, TNFRSF10A, TNFSRF10B, CASP8, DVL2,
FBXO11, BAX, CASP3, TCF4, FADD and VPS16). We
applied GSEA’s pre-ranked analysis to test for enrichment
of this gene set in the results from our screen. We found
no significant trend, suggesting that we had failed to pick
up most of the previous known genes involved in TRAIL
killing (normalized enrichment score (NES) = 1.64,
P = 0.097). To determine if this was due to a real effect
being hidden by the off-target effects, we removed any
siRNA containing an enriched seed sequence from our
data and reanalysed the screening data. The ranking of
siRNAs under this regime is available in Additional File 3.
Under this new analysis regime, there was a significant
enrichment of genes previously identified as being
involved in TRAIL-induced apoptosis when GSEA was
used to test for enrichment of gene set described above.
(NES = 1.64, P = 0.02). Thus, dividing screen hits accord-
ing to on and off-target effects not only reduces noise in
the screens but also can result in significant gains in sensi-
tivity as well.
Identification of miRNAs affecting sensitivity to TRAIL-
induced apoptosis
Transfecting siRNAs to knock-down target genes is
equivalent to over-expressing miRNAs of the same
sequence as the siRNA. If many of the siRNAs that
score well in our screen are exerting their effect through
miRNA-like effects determined by a set of common
seed sequences we reasoned that we might be able iden-
tify miRNAs with the same seed sequences and this
m i g h tb ea ni n d i c a t i o nt h a tt h e s em i R N A sa r ei n v o l v e d
in regulating TRAIL-induced apoptosis. We searched a
s e to fs e e ds e q u e n c e sf o u n di nh u m a nm i R N A sd o w n -
loaded from the miRBase database (version 10.0). We
identified three miRNAs whose seed sequences were the
same as those identified above (Table 3).
One of these miRNAs (miR-145) has previously
been implicated in the regulation of TRAIL induced
0%
20%
40%
60%
80%
100%
120%
siGL2 siGL2+mut seed siGL2+Seed siCasp8
siR N A
S
u
r
v
i
v
a
l
 
r
e
l
a
t
i
v
e
 
t
o
 
u
n
t
r
e
a
t
e
d
 
c
e
l
l
s
p < 2.5 × 10 -3
Figure 3 The seed sequence ACTTGA protects cells from TRAIL-induced cell death. HeLa cells were transfected with siRNAs targeting
Caspase-8 (siCasp8), Luciferase (siGL2) or siRNAs where the siGL2 sequence had been altered to contain the seed sequence ACTTGA (siGL2
+seed) or the seed sequence ATCTGA (siGL2+mutseed). After 48 hrs the sensitivity to treatment with 0.5 μg/ml TRAIL was measured. Results are
shown relative to cells not treated with TRAIL. Error bars represent 1 standard deviation (n = 3 biological replicates each with 3 technical
replicates). Difference between siGL2-seed and siGL2-mutseed is significant (P < 2.5 × 10-3, t-test on log-transformed data).
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Page 7 of 12apoptosis [21]. miRNA-26a has also been implicated in
regulation of Caspase-3 levels [21]. MiR-26a is highly
expressed in chronic lymphocytic leukemia cell lines
which are often resistant to TRAIL-induced apoptosis,
while miR-145 is down-regulated in colorectal and pros-
tate carcinomas, which are generally sensitive to TRAIL-
induced apoptosis [40-43]. Interestingly it has recently
been shown that miR-26a is repressed by MYC [44].
Very little is known about miR-384.
To confirm of the ability of these miRNA to affect
sensitivity to TRAIL, we transfected HeLa cells with
mimics of these miRNAs and tested the sensitivity of
these cells to TRAIL-induced cell death (Figure 4).
Mimics of all three miRNAs had a significant effect on
the sensitivity of cells to TRAIL-induced cell death com-
pared to cells transfected with a mimic of a Caenorhab-
ditis elegans miRNA used as a negative control. In two
of the three cases (miR-26a and miR-145) this difference
was still significant after correction for multiple testing.
To test if the involvement of these miRNAs was specific
to HeLa cells or extends to other cell types, we
transfected DU145 (prostate carcinoma), HCT-116 and
SW480 (both colorectal carcinoma) cells with the same
miRNA mimics. The effects of the miRNA mimics were
similar in SW480 and DU145 cells to HeLa cells, while
in HCT-116 the effects were significant only in the case
of the mimic of miR-126a (Figure 4). This demonstrates
that these miRNAs may have an effect in regulating
TRAIL-induced cell death that extends beyond HeLa
cells. To the best of our knowledge this is the first time
that the involvement of miRNAs in a process has been
suggested from studying RNAi off-target effects.
Conclusions
We have executed a screen for regulators of the TRAIL
induced apoptosis pathway and identified a novel gene
involved in this pathway: PDE11A.W ea l s oc o n f i r m e d
the involvement of several genes previously identified in
connection with the TRAIL-induced apoptosis pathway.
The small size of the overlap with previous screens sug-
gests that these screens are not saturating and that
other genes involved in the pathway remain to be
identified.
Most previous reports of siRNAs functioning through
miRNA-like targeting mechanisms have reported iso-
lated examples of such effects. We identified a set of
seed sequences that are over-represented in siRNAs
identified as potential hits from the screen and a further
set of seed sequences that is generally enriched in high-
scoring siRNAs. We showed that one of these seed
Table 3 Enriched seeds that are present in human
miRNAs
Seed miRNA
ACTTGA has-miR-26a
ACTGGA has-miR-145
TAGGAA has-miR-384
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Figure 4 miRNAs containing enriched seeds protect a several cell types from TRAIL induced cell death. Cells were transfected with
miRNA mimics with same sequence as naturally occurring miRNAs that contain seed sequences enriched in high-scoring siRNAs, an miRNA
mimic with a sequence occurring in no human miRNA, or an siRNA targeting Caspase-8 as a positive control. After 48 hrs the sensitivity to
treatment with 0.5 μg/ml TRAIL was measured. Error bars represent 1 standard deviation (n = 3 bioligical replicates each with 3 technical
replicates, * represents results significantly different from the negative control (P < 0.05, students’ T-test on log-transformed data), ** are
significantly different after Bonferroni correction.
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siRNA active in our assay. This suggests that siRNAs
containing one of these seed sequences exert their
effects due, at least in part, to the presence of one of
these seed sequences. The use of a statistical enrichment
approach to identify seed sequences which are more
common in highly scoring siRNAs provides a more
complete picture of the influence of seed sequence dri-
ven off-target effects on screen results.
Where as previously off-target events have been
regarded as unfortunate anomalies (which can in some
circumstances be driven by miRNA-like targeting
through seed sequences), our findings provides support
for the hypothesis of Lin et al, that RNAi screens enrich
for siRNAs with off target effects and suggests that any
siRNA scoring highly in a screen is very likely to be
exerting at least part of its effect through off-target
e f f e c t .T h i ss u g g e s t st h a tagene targeted by two highly
scoring siRNAs in a screen may still be an off-target hit
as was the case here with TEGT. We recommend that
in future all screening results be regarded with suspicion
until they are confirmed by at least two siRNAs (prefer-
ably more) not used in the original screen, and do not
contain seed sequences found in high scoring siRNAs
from the screen.
Removing siRNAs containing enriched seed sequences
allowed us to show that siRNAs targeting genes known
to be involved in the TRAIL induced apoptosis pathway
were enriched in high-scoring siRNAs. This suggests
that identifying enriched seed sequences and removing
siRNAs containing them from analysis in the future will
aid with such investigations.
One obvious approach to combating such off-target
effects would be to exclude siRNA with common seed
sequences at the design stage (as is the case for at least
one commercial siRNA design algorithm). While this
may exclude siRNAs with the largest number of
off-target effects (although it clearly won’tp r e v e n ta l l
seed-driven off-target effects), seeds from endogenous
miRNAs are not necessarily the ones that are most
common in 3’ UTRs. While siRNAs containing the
s e e d so fe n d o g e n o u sm i R N A sm a yh a v ef e w e rt a r g e t s ,
their targets are likely to have some degree of functional
relation, and are therefore more likely to have a strong
functional effect on the cell. Excluding siRNAs contain-
ing the top 10% of 6 mer seed sequence by frequency
would have removed 6 of the 17 seed sequences we
found to be enriched, but none of the seed sequences
we identified that are found in endogenous miRNAs
(data not shown). Excluding so many seed sequences
also greatly reduces the design space for siRNAs
and will result is more siRNAs sharing the same seed
sequences (and, if off-target effects are driven by seed
sequences, the same off-target effects).
Finally we used the enriched seed sequences to iden-
tify miRNAs that may be involved in TRAIL-induced
apoptosis, identifying miRNAs miR-26a, miR-145 and
miR-384 as affecting TRAIL-induced cell death in a
range of cell types. Further work will be needed to
examine if these miRNAs have an endogenous role in
regulating the TRAIL-induced apoptosis pathway. This
analysis allows additional information to be gathered
from the results of RNAi screening and turns potentially
confounding off-target effects into a new source of
information for the process being studied.
miRNAs present an attractive candidate for controllers
of sensitivity to TRAIL-induced apoptosis as they can
control many genes simultaneously, allowing those
changes necessary to transform cells to be linked to
changes sensitizing them to TRAIL-induced apoptosis.
Methods
Cells and cell culture
HeLa cells were obtained from ATCC (#CCL-2) and
were maintained in Modified Eagle’s medium (Sigma-
Aldrich) supplemented with 10% Fetal Bovine Serum,
2 mM L-Glutamine, 1× Non essential amino acids, peni-
cillin and streptomycin. SW480, HCT116 and DU145
cells were a kind gift from Prof. Mike Stratton. DU145
cells were maintained in the same media as HeLa cells.
SW480 cells were maintained in Leibovitz’sL - 1 5M e d -
ium (Sigma-Aldrich) supplemented with 10% Fetal
Bovine Serum, 2 mM L-Glutamine, penicillin and strep-
tomycin. HCT116 cells were maintained in McCoy’s5 a
(Sigma-Aldrich) supplemented with 10% Fetal Bovine
Serum, 2 mM L-Glutamine, penicillin and streptomycin.
siRNAs, miRNA mimics and transfection
Individual siRNAs were obtained from either Invitrogen,
Qiagen, Ambion or Dharmacon. Sequences and suppli-
e r so fs i R N A si sl i s t e di na d d i t i o n a lf i l e4 .m i R N A
mimics were obtained from Dharmacon. Library siRNAs
were from the Qiagen Druggable Genome Library v2.
Cells were transfected with 2.5 pmol siRNA in 96-well
plates or 12.5 pmol siRNA in 24-well plates using Lipo-
fectamine 2000 (Invitrogen) according to manufacturer’s
instructions for each cell type.
Assay for sensitivity to TRAIL-induced apoptosis
For HeLa cells, 3,000 cells were seeded into the well of a
96 well optilux plate (BD Bioscience), in antibiotic free
media. 24 hours later cells were transfected with siRNA.
After a further 48 hours the number of cells present was
measured by incubating for 3 hours with 10% alamarBlue
reagent (AbD Serotec, Oxford, UK) before reading flour-
escence (excitation: 544 nm, emission: 590 nm) using a
fluorescent plate reader (Molecular Devices, Sunnyvale,
CA). Cells were treated with 0.5 μg/ml recombinant
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and number of cells present was reanalysed as above.
siRNA screen
12,190 siRNAs from the Qiagen druggable genome
library v2 were arrayed into 96-wells plates along with
two duplicates of the siRNAs targeting Caspase-8, BID
and DIABLO as positive controls, two duplicates of an
siRNA targeting siKIF11 as a transfection control, and
four wells containing three different negative controls
(siNeg1, siNeg2 and siGFP). The siRNAs were trans-
fected into HeLa cells and the effect on TRAIL induced
measured as described above. The screen was performed
in duplicate. Plate were quality controlled by measuring
the dynamic range between positive control transfected
wells and negative control transfected wells, plates
where the positive control was not twice the negative
control were repeated.
Data analysis was performed using the cellHTS pack-
age in R/Bioconductor [45]. Briefly, the bottom 20%
wells for cell survival before TRAIL treatment were
removed from analysis. Survival was calculated by divid-
ing post treatment fluorescence by pre-treatment flour-
escence and the resulting ratio log-transformed and
normalized to plate median. Each well was converted to
a z score using the median and median absolute devia-
tion for each repeat:
z x median x median absolute deviation x     .
The minimum of the two scores for each siRNA was
selected to represent that siRNA. See cellHTS report in
supplementary information for analysis script.
Confirmation of screen hits
For each gene targeted by an siRNA in the top 20 scoring
siRNAs, both siRNAs in the library were retested in tripli-
cate. Where only one siRNA targeting a gene had a signifi-
cant effect a further two siRNAs were obtained. siRNAs
were tested for their effect on Caspase-3/7 activity. 3,000
cells were seeded in optilux plates and transfected with
siRNA as described above. 48 hours after transfection cells
were incubated with 0.5 μg/ml recombinant TRAIL in
serum free media for 6 hours and the level of Caspase-3/7
measured using the Caspase-glo 3/7 kit (Promega) accord-
ing to manufacturer’s instructions.
To measure the effect of siRNAs on mRNA levels,
15,000 cells were transfected with 12.5 pmol siRNA using
0.6 μl Lipofectamine 2000 and after 48 hours RNA pre-
pared using the SV Total RNA isolated kit (Promega),
and cDNA prepared using Superscript II (Invitrogen).
SYBR green qPCR was performed using qPCR Master-
Mix (Eurogentec) with primers designed to amplify the
transcript of interest or ACTB or GAPDH. All primers
were tested to measure amplification efficiency. See addi-
tional file 5 for primer sequences. Relative quantities
were calculated using the qBase software [46].
Identification of enriched seed sequences
To test the significance of observing the same seed
sequence in multiple siRNA from the top 20 siRNAs,
t h es e e ds e q u e n c eo fa l ls i R N A si nt h el i b r a r yw e r e
extracted. Samples of twenty seed sequences were
selected at random, and the number of times seed
sequences appeared counted. This was repeated 5,000
times for both hexamer and heptamer seed sequences
and the number of times any seed sequence appeared
more than one was counted.
To use GSEA to detect enriched seed sequences,
“gene-sets” were built containing the each of the siRNAs
containing at particular seed sequence. The GSEA desk-
top application’s pre-ranked analysis option was used to
test if these sets were enriched in high-scoring siRNAs.
This was repeated for both hexamer and heptamer seed
sequences.
Additional file 1: Complete screen results (screen_results.zip).
Complete results from the siRNA, presented as a mini-website as
produced by the cellHTS software
Additional file 2: Supplementary figures (supplementary_figures.
pdf). Figures S1 and S2 containing detailed results from confirmation
experiments for all 16 genes targeted by siRNAs from the screen which
reproducibly reduce sensitivity to TRAIL-induced cell death.
Additional file 3: Ranking of siRNAs after removal of siRNAs with
enriched seed sequences (no_enriched_seeds.csv). Ranking of siRNAs
used in the screen according to their score, after any siRNA containing
an enriched seed had been removed and data reanalysed.
Additional file 4: Sequences of siRNAs used (siRNAs.csv). List of
sequences, suppliers and catalogue numbers for non-library siRNAs.
Additional file 5: Sequences of qRT-PCR primers (primers.csv). List of
primer sequences used along with product lengths and amplification
efficiency for each pair.
Abbreviations
GSEA: Gene Set Enrichment Analysis; miRNA: microRNA; RNAi: RNA
interference; siRNA: small interfering RNA; TRAIL: TNF related apoptosis
inducing ligand.
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